OTCMKTS:VDRM ViaDerma (VDRM) Stock Price, News & Analysis $0.0004 0.00 (0.00%) As of 05/29/2026 10:41 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartShort InterestBuy This Stock About ViaDerma Stock (OTCMKTS:VDRM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ViaDerma alerts:Sign Up Key Stats Today's Range$0.0004▼$0.000450-Day Range N/A52-Week Range$0.0001▼$0.01Volume140,000 shsAverage Volume94,146 shsMarket CapitalizationN/AP/E Ratio0.00Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ViaDerma, Inc. (OTCMKTS: VDRM) is a dermatology-based healthcare company focused on the research, development and commercialization of proprietary topical skin-therapy products. Leveraging a patented elemental skin-therapy platform, the company designs formulations aimed at accelerating skin recovery, improving hydration and enhancing barrier function. Its product development process combines principles of biochemistry with clinical dermatology to address conditions ranging from dryness and irritation to minor wounds and abrasions. The company’s flagship offerings include the Return2Life™ line of topical creams and lotions, which are formulated with a unique blend of essential minerals and electrolytes. These over-the-counter products are intended for immediate skin relief and longer-term restoration of the epidermal barrier. ViaDerma’s product portfolio is positioned to serve healthcare providers, first responders and retail consumers seeking scientifically driven skin-care solutions. ViaDerma distributes its products primarily throughout the United States via multiple channels, including direct-to-consumer e-commerce platforms, partnerships with dermatology clinics and healthcare institutions, and select retail outlets. The company works closely with licensed practitioners and medical facilities to expand awareness of its formulations for use in both acute care settings and daily skin-care regimens. Founded with the goal of translating cutting-edge skin-science into practical therapies, ViaDerma is led by a management team with backgrounds in pharmaceutical formulation, clinical research and dermatology. Headquartered in Florida, the company continues to advance its pipeline through ongoing R&D efforts, strategic collaborations and the pursuit of additional patent protections to support its long-term growth in the dermatological market.AI Generated. May Contain Errors. Read More Receive VDRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ViaDerma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. VDRM Stock News HeadlinesViaDerma Inc (VDRM) Analyst ResearchApril 26, 2026 | nasdaq.comViaDerma Announces Posting of Annual Report and Ongoing Evaluation of Public Status in Response to Market ChangesJuly 16, 2025 | finance.yahoo.comRead this warning immediatelyPorter Stansberry, founder of one of the world's largest financial research firms, says he's breaking the biggest story of his 26-year career. A famous historian whose books have sold over 45 million copies in 65 languages is warning of a structural shift so large it has only one historical parallel - 1776. One Stanford economist calls it 'the biggest change ever - bigger than electricity, bigger than the steam engine.' Stansberry outlines the stocks to buy, the stocks to sell, and three money moves to position yourself on the right side of this shift.May 30 at 1:00 AM | Porter & Company (Ad)ViaDerma, Inc. Confirms Ongoing Operations and Commitment to Regulatory ComplianceJune 4, 2025 | globenewswire.comViaDerma, Inc. Strengthens Global Expansion with New Dubai Office and Progress Towards Product Registration in IndiaJanuary 21, 2025 | finance.yahoo.comViaDerma Announces Significant 2024 Achievements and International ExpansionDecember 10, 2024 | markets.businessinsider.comViaDerma, Inc. Reports Strong Financial Results for Q2 2024, Achieving Positive Net Income and Significant Cash Flow GrowthOctober 3, 2024 | finance.yahoo.comViaDerma Completes First Shipment of 500,000 Units to NigeriaSeptember 10, 2024 | stockhouse.comSee More Headlines VDRM Stock Analysis - Frequently Asked Questions How have VDRM shares performed this year? ViaDerma's stock was trading at $0.0002 at the beginning of 2026. Since then, VDRM stock has increased by 100.0% and is now trading at $0.0004. How do I buy shares of ViaDerma? Shares of VDRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ViaDerma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ViaDerma investors own include Tesla (TSLA), Dominari (DOMH), Co-Diagnostics (CODX), CEA Industries (CEAD), Organicell Regenerative Medicine (BPSR), AutoZone (AZO). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:VDRM CIKN/A Webviadermalicensing.com Phone(310) 734-6111FaxN/AEmployees75Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E Ratio0.00 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:VDRM) was last updated on 5/30/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredPresident Trump just sparked a stock market MELT UPThe real reason Musk, Huang, Cook, and Fink just flew to Beijing Last week, the CEOs of Nvidia, Apple, Spac...Stansberry Research | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ViaDerma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ViaDerma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.